Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …

The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

Treatment of solid cancers with chimeric antigen receptor (CAR) T cells is plagued by the
lack of ideal target antigens that are both absolutely tumor specific and homogeneously …

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

INTRODUCTION TP53 (tumor protein P53), a tumor suppressor gene, is the most commonly
mutated cancer-driver gene. Nevertheless, drugs that target mutant p53, the protein product …

The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …